Eli Lilly developed it and first reported it in the Phase 2 obesity trial by Jastreboff et al
Safety signals identified through extended follow-up include: Gastrointestinal effects : Nausea, vomiting, and diarrhea remain the most common adverse events, typically diminishing over time but causing discontinuation in approximately 57% of patients Gallbladder disease : Increased incidence of cholelithiasis and cholecystitis, possibly associated with weight loss, though the exact mechanism remains under investigation Diabetic retinopathy : Risk of complications, particularly with rapid glycemic improvement in patients with pre-existing retinopathy Acute kidney injury : Risk associated with severe gastrointestinal adverse events leading to dehydration Pancreatitis : Rare cases reported, though causality remains uncertain
This is a tolerance-building dose, not a therapeutic one
Meanwhile, the outer membrane will rupture, and proteins, such as cytochrome c and apoptosis-inducing factor (AIF), will be released from the intermembrane space into the cytosol, triggering apoptosis [190, 191]
Experience superior antioxidant support with our bioavailable formula, surpassing standard glutathione supplements
